Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Colorectal Cancer

    Philadelphia, PA

    Search
    Colorectal Cancer
    Philadelphia, PA
    Show Map
    Map View
    Philadelphia, PA

    Popular Searches

    By Condition

    Depression Clinical Trials in Pennsylvania

    Anxiety Clinical Trials in Pennsylvania

    Schizophrenia Clinical Trials in Pennsylvania

    ADHD Clinical Trials in Pennsylvania

    Bipolar Disorder Clinical Trials in Pennsylvania

    Multiple Sclerosis Clinical Trials in Pennsylvania

    Autism Clinical Trials in Pennsylvania

    Treatment Resistant Depression Clinical Trials in Pennsylvania

    Borderline Personality Disorder Clinical Trials in Pennsylvania

    Social Anxiety Disorder Clinical Trials in Pennsylvania

    Parkinson's Disease Clinical Trials in Pennsylvania

    Alzheimer's Disease Clinical Trials in Pennsylvania

    By Location

    Clinical Trials near Philadelphia, PA

    Clinical Trials near Pittsburgh, PA

    Clinical Trials near Hershey, PA

    Clinical Trials near Allentown, PA

    Clinical Trials near Danville, PA

    Clinical Trials near Bethlehem, PA

    Clinical Trials near Duncansville, PA

    Clinical Trials near York, PA

    Clinical Trials near Erie, PA

    Clinical Trials near Wynnewood, PA

    Clinical Trials near Lancaster, PA

    Clinical Trials near Wilkes-Barre, PA

    Other People Viewed

    By Subject

    Top Breast Cancer Clinical Trials near Philadelphia, PA

    Top Prostate Cancer Clinical Trials near Philadelphia, PA

    Top Clinical Trials near Philadelphia, PA

    15 Weight Loss Trials near Philadelphia, PA

    Top Depression Clinical Trials near Philadelphia, PA

    27 Multiple Sclerosis Trials near Philadelphia, PA

    Top Lung Cancer Clinical Trials near Philadelphia, PA

    25 Autism Trials near Philadelphia, PA

    48 Alzheimer's Disease Trials near Philadelphia, PA

    Top Colorectal Cancer Clinical Trials near Raleigh, NC

    Top Colorectal Cancer Clinical Trials near Ventura, CA

    Top Colorectal Cancer Clinical Trials near Columbia, SC

    By Trial

    Etrumadenant-Based Combinations for Colorectal Cancer

    Single Port Robotic Surgery for Colorectal Cancer

    Educational Website for Colorectal Cancer

    Exercise for Colorectal Cancer

    Personalized Cancer Vaccine for Pancreatic and Colorectal Cancer

    Legal Support for Colorectal Cancer

    Pemigatinib for Colorectal Cancer

    Plant-Based Diet for Colorectal Cancer

    Dasatinib + Venetoclax for Chronic Myelogenous Leukemia

    TAS-102 for Colorectal Cancer

    Bowel Management Program for Colorectal Cancer

    Pembrolizumab for Adrenocortical Cancer

    Related Searches

    Top Sickle-cell-anemia Clinical Trials

    Top Leiomyosarcoma Clinical Trials

    Top Thyroid Clinical Trials

    Top Dry-eye Clinical Trials

    Armed Activated T-Cells for Pancreatic Cancer

    CTX112 for Lupus

    Virtual Reality for Pain Management in Burn Patients

    E-cigarettes for COPD

    Tranexamic Acid for Subdural Hematoma

    Avelumab + M1774 for Endometrial Cancer

    Gene Therapy for Fabry Disease

    Metformin for Immune Dysregulation in Drug Users

    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      104 Colorectal Cancer Trials near Philadelphia, PA

      Power is an online platform that helps thousands of Colorectal Cancer patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      Amivantamab + FOLFIRI for Colorectal Cancer

      Philadelphia, Pennsylvania
      The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus either cetuximab or bevacizumab and FOLFIRI given to participants with Kirsten rat sarcoma viral oncogene/ neuroblastoma RAS viral oncogene homolog (KRAS/ NRAS) and v-raf murine sarcoma viral oncogene homolog B (BRAF) wild-type recurrent, unresectable or metastatic colorectal cancer who have previously received chemotherapy.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:ILD, Second Malignancy, HER2-positive, Others
      Must Not Be Taking:Irinotecan, EGFR Agents, MET Agents

      700 Participants Needed

      Amivantamab + Chemotherapy vs Cetuximab + Chemotherapy for Colorectal Cancer

      Philadelphia, Pennsylvania
      The purpose of this study is to compare how long the participants are disease-free (progression-free survival) when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, oxaliplatin (mFOLFOX6) or 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus cetuximab and mFOLFOX6 or FOLFIRI in adult participants with Kirsten rat sarcoma viral oncogene homolog (KRAS)/ Neuroblastoma RAS viral oncogene homolog (NRAS) and v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) wild type (WT) unresectable or metastatic left-sided colorectal cancer.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:ILD, Pneumonitis, Pulmonary Fibrosis, Others
      Must Not Be Taking:EGFR Inhibitors, MET Inhibitors

      1000 Participants Needed

      Sotorasib + Panitumumab + FOLFIRI for Colorectal Cancer

      Philadelphia, Pennsylvania
      The aim of this study is to compare progression free survival (PFS) in treatment-naïve participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevacizumab-awwb.
      No Placebo Group
      Prior Safety Data
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Brain Metastases, Leptomeningeal Disease, Others

      450 Participants Needed

      XL092 + Atezolizumab vs Regorafenib for Colorectal Cancer

      Philadelphia, Pennsylvania
      This trial is testing a combination of two drugs, XL092 and atezolizumab, against another treatment in patients with a specific type of colorectal cancer that has spread and not responded to standard treatments. The goal is to see if the new combination can better stop cancer growth and help the immune system fight the cancer.
      No Placebo Group
      Prior Safety Data
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Brain Metastases, Uncontrolled Illness, Pregnancy, Others
      Must Not Be Taking:Corticosteroids, Immunosuppressives, Kinase Inhibitors, Others

      901 Participants Needed

      Nivolumab-relatlimab Combo for Colorectal Cancer

      Philadelphia, Pennsylvania
      This trial is testing a combination of two drugs, relatlimab and nivolumab, for patients with a certain type of colorectal cancer who haven't responded to other treatments. The drugs help the immune system attack the cancer.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Untreated CNS Metastases, Refractory Hypertension, Others
      Must Not Be Taking:Immunotherapy, Regorafenib, TAS-102

      700 Participants Needed

      Vitamin D3 + Chemotherapy + Bevacizumab for Colorectal Cancer

      Philadelphia, Pennsylvania
      This trial is testing if vitamin D3 along with regular cancer drugs and another drug that helps the immune system can better treat colorectal cancer that has spread. Vitamin D3 may help the body use essential minerals, making the cancer drugs more effective. Vitamin D3 has been shown to slow down cancer cell growth and help them mature, and it has been effective in reducing intestinal tumors in animal studies.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Hypertension, Heart Failure, Bleeding, Others
      Must Not Be Taking:Thiazides, Corticosteroids, Lithium, Others

      455 Participants Needed

      Eflornithine + Sulindac for Colorectal Cancer Prevention

      Camden, New Jersey
      The investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing a three-year event rate of adenomas and second primary colorectal cancers in patients previously treated for Stages 0 through III colon or rectal cancer.
      Prior Safety Data
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:High Cardiovascular Risk, Uncontrolled Hypertension, Gastric/duodenal Ulcer, Others
      Must Not Be Taking:Corticosteroids, NSAIDs, Anticoagulants

      354 Participants Needed

      Fruquintinib for Colorectal Cancer

      Philadelphia, Pennsylvania
      High blood pressure (hypertension) is a known side effect of the treatment with fruquintinib. Current research does not provide a clear answer whether minority groups such as Black/African American and/or Hispanic/Latino with refractory metastatic colorectal cancer (mCRC) have a bigger risk of higher blood pressure after treatment with fruquintinib. The main aim of this study is to learn how often adults of a minority group experience hypertension after they have been treated with fruquintinib for refractory mCRC. Other aims are to learn how safe fruquintinib is and how well it is tolerated by participants. Participants will receive fruquintinib in 4-week treatment cycles until their condition worsens, they do no longer tolerate the treatment or stop the treatment for other reasons. After the last treatment, participants will be checked upon every 3 months until study completion.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4

      Key Eligibility Criteria

      Disqualifiers:Uncontrolled Hypertension, Cardiovascular Disease, Others
      Must Not Be Taking:Anticoagulants, TKIs, CYP3A4 Inducers

      78 Participants Needed

      GSK4418959 for Colorectal Cancer

      Philadelphia, Pennsylvania
      Solid tumours are abnormal lumps of tissue that can occur in different parts of the body. The tumours involved in this study have specific genetic characteristics that can make them more aggressive and challenging to treat. The study will test whether GSK4418959 alone or in combination with a PD-1 inhibitor agent can decrease tumor size, is safe, well-tolerated, and how amounts of the study drug decrease in the body over time.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Uncontrolled Brain Metastases, Severe Liver Fibrosis, Active Autoimmune Disease, Others
      Must Not Be Taking:WRN Inhibitors

      73 Participants Needed

      Leronlimab + Standard Treatment for Colorectal Cancer

      Philadelphia, Pennsylvania
      This is an open label, randomized, two arm, multi-center study to explore the effect of leronlimab on the overall response rate/ overall survival and safety and tolerability when used in combination with trifluridine and tipiracil + bevacizumab in patients with CCR5+, MSS, mCRC who have progressed on prior treatment before participating in the study. The main questions this study aims to answer are: 1. Can leronlimab, in combination with standard of care therapies trifluridine and tipiracil+ bevacizumab, increase the objective response rate in persons with CCR5+, MSS, mCRC who have progressed on prior treatment before participating in the study. 2. Is leronlimab safe and well tolerated in these subjects when used in combination with standard of care therapies trifluridine and tipiracil+ bevacizumab.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Coronary Heart Disease, Hepatitis B, Others
      Must Not Be Taking:Anabolic Steroids

      60 Participants Needed

      Cancer Vaccines for Lynch Syndrome

      Philadelphia, Pennsylvania
      This trial tests a vaccine and an immune booster to prevent cancer in people with Lynch syndrome. The vaccine teaches the body to fight cancer, and the booster makes this process stronger. Vaccines have shown robust potential for preventing Lynch syndrome cancers.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Immunodeficiency, HIV, Hepatitis, Others
      Must Not Be Taking:Corticosteroids, Immunosuppressants, Others

      186 Participants Needed

      Vaccine Nous-209 for Lynch Syndrome

      Philadelphia, Pennsylvania
      This trial tests the safety and effectiveness of the Nous-209 vaccine in patients with Lynch syndrome, a condition that increases cancer risk. The vaccine uses man-made proteins to help the immune system recognize and fight cancer cells. Researchers aim to see if the vaccine can prevent cancer development in these high-risk patients. Nous-209 is a ready-to-use cancer vaccine that targets specific markers found in certain types of tumors.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Active Cancer, HIV, Hepatitis, Others
      Must Not Be Taking:Corticosteroids, Immunosuppressants, NSAIDs, Others

      45 Participants Needed

      DSP107 + Atezolizumab for Solid Tumors

      Philadelphia, Pennsylvania
      Part 1: A first-in-human, open-label, Phase I dose escalation study of DSP107 monotherapy and combination therapy with atezolizumab in patients with advanced solid tumors. Part 2: Preliminary efficacy assessment of DSP107 in combination with atezolizumab in second or third line treatment of non small cell lung cancer. Preliminary efficacy assessment of DSP107 as a single agent or in combination with atezolizumab in third line treatment of colorectal cancer.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:CNS Metastases, Autoimmune Disease, Liver Disease, Others
      Must Not Be Taking:Immunosuppressants, Immunostimulants, Atezolizumab, Others

      125 Participants Needed

      Combination Chemotherapy for Colorectal Cancer

      Philadelphia, Pennsylvania
      This trial tests a combination of three drugs to treat advanced colorectal cancer. It targets patients whose cancer has spread or cannot be surgically removed. The drugs work together to kill cancer cells, block their growth, and help the immune system fight the cancer. Oxaliplatin is a new drug that has been recently added to initial treatments for advanced colorectal cancer.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Hypertension, Heart Failure, Thrombosis, Others
      Must Not Be Taking:Anti-cancer Therapy

      42 Participants Needed

      Etrumadenant-Based Combinations for Colorectal Cancer

      Philadelphia, Pennsylvania
      This randomized phase 1b/2 open-label study will evaluate the antitumour activity and safety of etrumadenant (AB928) treatment combinations in participants with metastatic colorectal cancer.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:CNS Metastases, Cardiovascular Disease, Autoimmune Disease, Others
      Must Not Be Taking:Antibiotics, Antivirals, Immunostimulants, Vaccines

      227 Participants Needed

      Vaccine Therapy for Advanced Colon Polyps

      Philadelphia, Pennsylvania
      This randomized phase II clinical trial studies how well MUC1 peptide-poly-ICLC adjuvant vaccine works in treating patients with newly diagnosed advanced colon polyps (adenomatous polyps). Adenomatous polyps are growths in the colon that may develop into colorectal cancer over time. Vaccines made from peptides may help the body build an effective immune response to kill polyp cells. MUC1 peptide-poly-ICLC adjuvant vaccine may also prevent the recurrence of adenomatous polyps and may prevent the development of colorectal cancer.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:40 - 70

      Key Eligibility Criteria

      Disqualifiers:Colorectal Cancer, Other Malignancy, Autoimmune Diseases, Others
      Must Not Be Taking:Immunomodulators, Oral Corticosteroids

      110 Participants Needed

      Novel Interventions for Colorectal Cancer

      Philadelphia, Pennsylvania
      The main purpose of this study is to evaluate the safety and efficacy of novel study interventions and combinations in participants with Colorectal Cancer (CRC).
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:CNS Metastases, Autoimmune Disorders, Hypertension, Others

      120 Participants Needed

      Combo Therapy for Colorectal Cancer

      Camden, New Jersey
      This is a Phase 1b/2 study to investigate the efficacy and safety of LBL-007 plus tislelizumab when administered in combination with bevacizumab plus fluoropyrimidine, and LBL-007 in combination with bevacizumab plus fluoropyrimidine versus bevacizumab plus fluoropyrimidine to participants with colorectal cancer.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:BRAF V600E, MSI-H, DMMR, Others
      Must Not Be Taking:Anti-EGFR, T-cell Checkpoint

      113 Participants Needed

      Novel Cancer Therapies for Colorectal Cancer

      Philadelphia, Pennsylvania
      COLUMBIA-1 is a Phase 1b/2 platform study to evaluate the safety and efficacy of standard of care (FOLFOX plus bevacizumab) alone and in combination with novel oncology therapies in first-line metastatic microsatellite-stable colorectal cancer (MSS-CRC).
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      61 Participants Needed

      Adaptive Radiotherapy for Rectal Cancer

      Philadelphia, Pennsylvania
      The goal of this clinical trial is to find out if giving extra adaptive radiation therapy after standard chemoradiation treatment is safe and helpful for people with rectal cancer. The main questions the study aims to answer are: * Can this approach help target the most aggressive cancer cells more accurately, while protecting nearby healthy tissue? * Can it reduce the side effects that people may experience during treatment? Participants will: * First receive standard treatment: radiation (45 Gy in 25 sessions) along with a chemotherapy pill called capecitabine. * Then get extra radiation using MRI scans every two weeks to adjust the treatment based on how the tumor responds. * Use a small balloon during treatment to help aim the radiation and protect healthy areas. * Finally, receive additional chemotherapy (such as FOLFOX) for four months.
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Prior Rectal Cancer Treatment, Anal Canal Involvement, Prior Pelvic Radiation, Active Cancer Within 3 Years, Uncontrolled Illness, Others
      Must Be Taking:Capecitabine, FOLFOX

      37 Participants Needed

      Why Other Patients Applied

      "I had two chemotherapy regímens without success, three surgeries during which the tumor could not be resected. These clinical trials are a light of hope for me and my family (I have a five year old child) and I have read about cases of success in other types of cancer with this treatment. I think that I am a perfect candidate for this tríal. Thank you."

      UM
      Pancreatic Cancer PatientAge: 48

      "I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

      ID
      Pancreatic Cancer PatientAge: 40

      "My mom has cholangiocarcinoma with bone mts (FGFR2 mutation). She really needs this trial to survive. She’s active and her analysis is ok, but we have very limited other options. Hope to work with a high-quality clinic to prolong her quality and duration of life."

      OF
      Cholangiocarcinoma PatientAge: 54

      "I've had radiation and as far as I know I’m in remission, but my brother passed away with the same condition. I don’t mind helping research for a cure... my husband passed away with pancreatic cancer. I've had a stepdaughter that passed away with ovarian cancer at 20. I just think it’s time to knock cancer out! I'd really like to help find better treatments by participating in a trial."

      EQ
      Lung Cancer PatientAge: 70

      "I've tried chemotherapy and radiation but the cancer recurred. My oncologist suggested that I might want to try a clinical trial given my situation. Just starting to research, hoping to learn more."

      FR
      Lung Cancer PatientAge: 71
      Match to a Colorectal Cancer Trial

      CT-95 for Cancer

      Philadelphia, Pennsylvania
      This is a Phase 1a/1b open-label, dose escalation study to evaluate the safety and efficacy of CT-95 (study drug), a humanized T cell engaging bispecific antibody targeting Mesothelin, in subjects with advanced solid tumors associated with Mesothelin expression.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Active Infection, CAR-T Therapy, Others

      70 Participants Needed

      INBRX-109 for Solid Tumors

      Philadelphia, Pennsylvania
      This trial tests INBRX-109, a protein that attaches to harmful cells and signals the body to destroy them. It targets patients with conditions involving DR5, like certain cancers.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Age:12 - 85

      Key Eligibility Criteria

      Disqualifiers:Hematologic Malignancies, CNS Tumors, Liver Diseases, Others
      Must Not Be Taking:DR5 Agonists

      321 Participants Needed

      JANX008 for Advanced Cancer

      Philadelphia, Pennsylvania
      This study is a first-in-human (FIH), Phase 1/1b, open-label, multicenter dose escalation and dose expansion study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of JANX008 in adult subjects with advanced or metastatic carcinoma expressing EGFR.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Cardiovascular Diseases, Active Infection, Others
      Must Not Be Taking:EGFR-targeted, CD3 Engaging

      130 Participants Needed

      XL092 + Immuno-Oncology Agents for Solid Tumors

      Philadelphia, Pennsylvania
      This trial is testing a new drug called XL092 alone and with other cancer drugs in patients with advanced solid tumors. The goal is to see if these treatments can safely stop or slow tumor growth and help the immune system fight cancer more effectively.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Brain Metastases, Uncontrolled Illness, Pregnancy, Others
      Must Not Be Taking:Anticoagulants, Complementary Medicines

      1274 Participants Needed

      XL092 + Immunotherapy for Cancer

      Philadelphia, Pennsylvania
      This trial is testing a new drug called XL092 by itself and with two other drugs, atezolizumab and avelumab. It targets patients with advanced solid tumors who may not respond to current treatments. XL092 aims to stop cancer cells from growing, while atezolizumab and avelumab help the immune system fight the cancer. Atezolizumab is approved for various cancers, including breast and urothelial carcinoma, and has shown efficacy in combination with chemotherapy.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Brain Metastases, Uncontrolled Illness, Others
      Must Not Be Taking:Kinase Inhibitors, Anticancer Antibodies

      325 Participants Needed

      Ketone Supplement for Colorectal Cancer Prevention

      Philadelphia, Pennsylvania
      This trial is testing a BHB supplement, which is a type of ketone used for energy, in patients having a colonoscopy or flexible sigmoidoscopy. The goal is to see if the supplement is safe and if it changes the cells in the colon.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Diabetes, Cancer, Others

      20 Participants Needed

      AI-informed Screening Navigation for Colorectal Cancer

      Philadelphia, Pennsylvania
      This project aims to use machine learning algorithms (MLA) to identify and risk-stratify individuals between the ages of 45-49 who are more likely to have colorectal pathology and merit prioritized CRC screening and patient navigation. Patients deemed to be at higher risk for CRC by MLA will be randomized to an intervention group to receive risk-informed patient navigation and a usual care control group. The patient navigation will assist in completing either a fecal immunochemical test (FIT) or a colonoscopy. For the usual care control group, patients may still receive patient navigation for colonoscopy assistance. A referral to a nurse navigator can be initiated by a healthcare staff member in the following ways: 1) procedure scheduling staff will provide navigator's contact number if the patient expresses difficulty with obtaining a ride home 2) endoscopy staff and physicians can message navigator electronically 3) PCPs can place a navigation order in the EHR for patients deemed to need additional support such as with prep, education, transportation 4) providers will directly contact the director of the navigation system (Dr. Carmen Guerra) for referral.
      No Placebo Group

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Unphased
      Age:45 - 49

      Key Eligibility Criteria

      Disqualifiers:Prior CRC, Late-stage Cancer, Colectomy, Others

      7120 Participants Needed

      Outreach and Reminder Strategies for Colorectal Cancer Screening

      Philadelphia, Pennsylvania
      This is a 3-year pragmatic, randomized clinical trial among average-risk patients at diverse primary care practices who are overdue for colorectal (CRC) screening. This project aims to evaluate the effect of a centralized program that includes direct outreach to patients and visit-based, clinician directed nudges facilitated by the electronic health record (EHR) with follow-up text messaging on the uptake of CRC screening. The primary outcome is CRC screening completion at 3 years. Patient and clinician factors impacting the experience and effectiveness of the intervention will be explored through surveys and qualitative interviews.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:50 - 72

      Key Eligibility Criteria

      Disqualifiers:CRC History, Polyps, IBD, Others

      20000 Participants Needed

      Decision Aid Tool for Colorectal Cancer Screening

      Philadelphia, Pennsylvania
      Conduct a feasibility pilot RCT of a newly developed colorectal cancer screening (CRC) decision aid (DA) including 66 LHL adults 76-85 years recruited from community health centers. Hypotheses: Patients in the intervention group will be more likely to change their intentions to be screened with fewer patients with \<10 year LE and/or those with \>10 year LE and no risk factors intending to be screened and more with \>10 year LE and risk factors for CRC and/or those who have never been screened intending to be screened (primary outcome). The secondary outcomes are that the patients in the intervention group will have 1. increased knowledge of CRC screening options and the benefits and risks of these options; 2. increased SDM engagement; and 3. find the DA acceptable. Investigators also anticipate that at least 50% of eligible participants will choose to participate in the study.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:75 - 85

      Key Eligibility Criteria

      Disqualifiers:Dementia, Colorectal Cancer History, Others

      60 Participants Needed

      Colonoscopy vs FIT Screening for Colorectal Cancer

      Philadelphia, Pennsylvania
      This trial compares two methods for colorectal cancer screening in people aged 50-75. One method uses a camera to find and remove precancerous growths, while the other checks for hidden blood in stool. The study aims to see which method better reduces cancer deaths over time.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:50 - 75

      Key Eligibility Criteria

      Disqualifiers:Colorectal Cancer, Inflammatory Bowel Disease, Others

      50126 Participants Needed

      1234

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do Colorectal Cancer clinical trials in Philadelphia, PA pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do Colorectal Cancer clinical trials in Philadelphia, PA work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Colorectal Cancer trials in Philadelphia, PA 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Philadelphia, PA for Colorectal Cancer is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Philadelphia, PA several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a Colorectal Cancer medical study in Philadelphia, PA?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest Colorectal Cancer clinical trials in Philadelphia, PA?

      Most recently, we added Adaptive Radiotherapy for Rectal Cancer, LY4337713 for Cancer and Educational Website for Colorectal Cancer to the Power online platform.